No Detail Found!

Serum PIVKA-II: reference interval of healthy population and establishment of its cutoff value for hepatocellular carcinoma diagnosis in Pakistan

Author(s)
Faryal Husnain Department of Chemical Pathology and Immunology, Chughtai Institute of Pathology, Lahore, Pakistan.
Muhammad Dilawar Khan Department of Chemical Pathology, Chughtai Institute of Pathology, Lahore, Pakistan
Omar Rasheed Chughtai Department of Histopathology, Chughtai Institute of Pathology, Lahore, Pakistan
Akhtar Sohail Chughtai Chief Executive, Chughtai Institute of Pathology, Lahore, Pakistan
Shakeel Ashraf Technologist, Department of Chemical Pathology, Chughtai Institute of Pathology, Lahore, Pakistan
Ahmed Yar Technologist, Department of Chemical Pathology, Chughtai Institute of Pathology, Lahore, Pakistan
Abstract
Protein induced by vitamin K absence II (PIVKA-II) is an upcoming and promising new biological marker cited as having a definitive role in the early detection and diagnosis of hepatocellular carcinoma (HCC). Preliminary research shows PIVKA-II reference intervals (RIs) in serum to have substantial racial disparities globally. Hence, this study aimed to determine the RIs and cut-of value of the serum PIVKA-II for the first time in healthy and patients with HCC in Pakistan. Methods: This cross-sectional study comprised 240 participants (120 diagnosed cases of HCC and 120 healthy individuals) registered at the Department of Chemical Pathology and Immunology, Chughtai Institute of Pathology, Lahore, Pakistan. The PIVKA-II serum level was analyzed using the Chemistry Analyzer through chemiluminescent micro-particle immunoassay. The RI was subsequently established using the percentile method. Results: In healthy Pakistani adults, the 95% RI for PIVKA-II was 15.55-43.03 mAU/ml, and the cut-of was 148.81 mAU/ml in HCC cases. The male participants, exhibited higher PIVKA-II levels than the females (p < 0.002). There were no significant diefrences in the serum levels of PIVKA-II with respect to age however variations were observed with respect to gender. Conclusion: Determination of the RI for serum PIVKA-II in healthy adult Pakistani individuals and a cut-of for HCC diagnosis emphasizes the growing need to establish and verify RIs of analytes at a larger scale in our population. Ideally all clinical laboratories should establish their own RIs.
Publication Details
Page(s) 259-264
Published Journal: Biomedica, Volume: 37, Issue: 4, Year: 2021

Request the full text from PASTIC

Keywords
Hepatocellular carcinoma, PIVKA-II, healthy controls, Alpha Feto Protein, cut-of value, Reference interval
References
Patel KK,Qavi AJ,Hock KG,Gronowski AM .2016 .Establishing reference intervals for HCG in postmenopausal women. Clin Biochem, 11(4-5) : 234-7.
Jones GR,Koetsier S. .2017 .Uptake of recommended common reference intervals for chemical pathology in Australia. , 54(3) : 395-7.
Sturgeon CM,Sprague S,Almond A,Cavalier E,Fraser WD,Algeciras-Schimnich A .2016 .Perspective and priorities for improvement of parathyroid hormone (PTH) measurement-A view from the IFCC Working Group for PTH. Clin Chim Acta, 10(5) : 42-7.
Ichihara K. .2014 .Statistical considerations for harmonization of the global multicenter study on reference values. Clin Chim Acta, 01(3) : 108-18.
Ichihara K,Ozarda Y,Barth JH,Klee G,Shimizu Y,Xia L .2016 .A global multicenter study on reference values: 2. Exploration of sources of variation across the countries. Clin Chim Acta, 09(6) : 83-97.
Horowitz GL,Altaie S,Boyd JC .2010 .Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. , 28 : 3-A3.
Ozarda Y,Ichihara K,Barth JH,Klee G .2013 .Protocol and standard operating procedures for common use in a worldwide multicenter study on reference values. -0249, 51(5) : 1027-40.
Stewart BW,Wild CP .2014 .. fr/Non-Series-Publications/ World-Cancer-Reports/World-Cancer-Report-2014, : .
Munaf A,Memon MS,Kumar P,Ahmed S,Kumar MB .2014 .Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV-cohort from liver clinics in Pakistan. APJCP, 15(18) : 7563-7.
Butt AS,Hamid S,Wadalawala AA,Ghufran M,Javed AA,Farooq O,Ahmed B .2013 .Hepatocellular carcinoma in native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viralhepatocellular carcinoma. BMC Res, 6(1) : 1756-3.
.2005 .Diagnosis of hepatocellular carcinoma. HPB (Oxford), 7(1) : 26-34.
Liebman HA,Furie BC,Tong MJ,Blanchard RA,Lo KJ,Lee SD .1984 .Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. NEJM, 31(22) : 1427-31.
Cui SX,Yu XF,Qu XJ .2016 .Roles and signaling pathways of des-γ- carboxyprothrombin in the progression of hepatocellular carcinoma. Can Invest, 20(9) : 459-64.
Yu R,Xiang X,Tan Z,Zhou Y,Wang H,Deng G .2016 .Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep, 6(9) : 35050.
Saitta C,Raffa G,Alibrandi A,Brancatelli S,Lombardo D,Tripodi G .2017 .PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine, 96(26) : .
Horn PS,Pesce AJ .2003 .Reference intervals: an update. Clin Chim Acta, 8981(03) : 00133-5.
Fujita K,Kinukawa H,Ohno K,Ito Y,Saegusa H,Yoshimura T .2015 .Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II. Clin Biochem, 07(18) : 1330-6.
Gandham G,Jayamohanan H,Ponnada B,Kumar A,Keechilat P .2020 .Correlation of serum PIVKA-II and AFP level with portal vein tumor thrombus and BCLC stage in newly diagnosed hepatocellular carcinoma patients. J Clin Oncol, 38(suppl) : .
Kim MJ,Bae KW,Seo PJ,Jeong IK,Kim JH,Lee BH .2006 .Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve. Korean J Gastroenterol, 12(3) : 404-11.
Viggiani V,Palombi S,Gennarini G,D'Ettorre G,De Vito C,Angeloni A .2016 .Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scand J Gastroenterol, 51(10) : 1257-62.
0

Citations

0

Downloads

33

Views